nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—HRH2—gastric juice—pancreatic cancer	0.0463	0.318	CbGeAlD
Loxapine—HTR3A—enteric nervous system—pancreatic cancer	0.0387	0.266	CbGeAlD
Loxapine—HTR7—enteric nervous system—pancreatic cancer	0.025	0.172	CbGeAlD
Loxapine—HTR2A—enteric nervous system—pancreatic cancer	0.0156	0.107	CbGeAlD
Loxapine—HTR3A—islet of Langerhans—pancreatic cancer	0.0037	0.0254	CbGeAlD
Loxapine—HRH2—digestive system—pancreatic cancer	0.00282	0.0194	CbGeAlD
Loxapine—HTR3A—digestive system—pancreatic cancer	0.00222	0.0153	CbGeAlD
Loxapine—ADRA2A—islet of Langerhans—pancreatic cancer	0.00175	0.0121	CbGeAlD
Loxapine—SLC6A4—digestive system—pancreatic cancer	0.00169	0.0116	CbGeAlD
Loxapine—ADRA2C—pancreas—pancreatic cancer	0.00155	0.0106	CbGeAlD
Loxapine—CHRM3—digestive system—pancreatic cancer	0.00151	0.0104	CbGeAlD
Loxapine—HTR7—digestive system—pancreatic cancer	0.00144	0.00987	CbGeAlD
Loxapine—ADRA2A—pancreas—pancreatic cancer	0.00123	0.00848	CbGeAlD
Loxapine—HRH1—digestive system—pancreatic cancer	0.00107	0.00737	CbGeAlD
Loxapine—HTR2A—digestive system—pancreatic cancer	0.000896	0.00616	CbGeAlD
Loxapine—Paraesthesia—Sunitinib—pancreatic cancer	0.000819	0.00249	CcSEcCtD
Loxapine—Dyspnoea—Sunitinib—pancreatic cancer	0.000813	0.00248	CcSEcCtD
Loxapine—Photosensitivity—Epirubicin—pancreatic cancer	0.000811	0.00247	CcSEcCtD
Loxapine—Loss of consciousness—Irinotecan—pancreatic cancer	0.000809	0.00246	CcSEcCtD
Loxapine—Cough—Irinotecan—pancreatic cancer	0.000803	0.00245	CcSEcCtD
Loxapine—Leukopenia—Gemcitabine—pancreatic cancer	0.000802	0.00245	CcSEcCtD
Loxapine—Renal failure—Docetaxel—pancreatic cancer	0.0008	0.00244	CcSEcCtD
Loxapine—Hypertension—Irinotecan—pancreatic cancer	0.000794	0.00242	CcSEcCtD
Loxapine—Jaundice—Docetaxel—pancreatic cancer	0.000793	0.00242	CcSEcCtD
Loxapine—Leukopenia—Fluorouracil—pancreatic cancer	0.000789	0.0024	CcSEcCtD
Loxapine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000787	0.0024	CcSEcCtD
Loxapine—Fatigue—Sunitinib—pancreatic cancer	0.000786	0.0024	CcSEcCtD
Loxapine—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000784	0.00239	CcSEcCtD
Loxapine—Cough—Gemcitabine—pancreatic cancer	0.000782	0.00238	CcSEcCtD
Loxapine—Constipation—Sunitinib—pancreatic cancer	0.00078	0.00238	CcSEcCtD
Loxapine—Hypertension—Gemcitabine—pancreatic cancer	0.000774	0.00236	CcSEcCtD
Loxapine—Asthenia—Tamoxifen—pancreatic cancer	0.000764	0.00233	CcSEcCtD
Loxapine—Convulsion—Fluorouracil—pancreatic cancer	0.000764	0.00233	CcSEcCtD
Loxapine—Chest pain—Gemcitabine—pancreatic cancer	0.000763	0.00233	CcSEcCtD
Loxapine—Agranulocytosis—Docetaxel—pancreatic cancer	0.00076	0.00231	CcSEcCtD
Loxapine—Confusional state—Irinotecan—pancreatic cancer	0.000757	0.00231	CcSEcCtD
Loxapine—Asthenia—Erlotinib—pancreatic cancer	0.000756	0.0023	CcSEcCtD
Loxapine—Pruritus—Tamoxifen—pancreatic cancer	0.000753	0.00229	CcSEcCtD
Loxapine—Oedema—Irinotecan—pancreatic cancer	0.000751	0.00229	CcSEcCtD
Loxapine—Photosensitivity—Doxorubicin—pancreatic cancer	0.000751	0.00229	CcSEcCtD
Loxapine—Chest pain—Fluorouracil—pancreatic cancer	0.00075	0.00229	CcSEcCtD
Loxapine—Pruritus—Erlotinib—pancreatic cancer	0.000745	0.00227	CcSEcCtD
Loxapine—Shock—Irinotecan—pancreatic cancer	0.000739	0.00225	CcSEcCtD
Loxapine—Nervous system disorder—Irinotecan—pancreatic cancer	0.000737	0.00224	CcSEcCtD
Loxapine—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000735	0.00224	CcSEcCtD
Loxapine—Oedema—Gemcitabine—pancreatic cancer	0.000732	0.00223	CcSEcCtD
Loxapine—Hepatitis—Docetaxel—pancreatic cancer	0.000731	0.00223	CcSEcCtD
Loxapine—Hypoaesthesia—Docetaxel—pancreatic cancer	0.000727	0.00222	CcSEcCtD
Loxapine—Cerebrovascular accident—Epirubicin—pancreatic cancer	0.000727	0.00222	CcSEcCtD
Loxapine—Confusional state—Fluorouracil—pancreatic cancer	0.000725	0.00221	CcSEcCtD
Loxapine—Oedema—Fluorouracil—pancreatic cancer	0.000719	0.00219	CcSEcCtD
Loxapine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000717	0.00219	CcSEcCtD
Loxapine—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000716	0.00218	CcSEcCtD
Loxapine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000705	0.00215	CcSEcCtD
Loxapine—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000704	0.00215	CcSEcCtD
Loxapine—Dizziness—Tamoxifen—pancreatic cancer	0.000704	0.00215	CcSEcCtD
Loxapine—Tachycardia—Fluorouracil—pancreatic cancer	0.000702	0.00214	CcSEcCtD
Loxapine—Hypotension—Irinotecan—pancreatic cancer	0.000702	0.00214	CcSEcCtD
Loxapine—Dizziness—Erlotinib—pancreatic cancer	0.000696	0.00212	CcSEcCtD
Loxapine—Hypotension—Gemcitabine—pancreatic cancer	0.000684	0.00208	CcSEcCtD
Loxapine—Insomnia—Irinotecan—pancreatic cancer	0.000679	0.00207	CcSEcCtD
Loxapine—Vomiting—Tamoxifen—pancreatic cancer	0.000677	0.00206	CcSEcCtD
Loxapine—Paraesthesia—Irinotecan—pancreatic cancer	0.000674	0.00205	CcSEcCtD
Loxapine—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.000673	0.00205	CcSEcCtD
Loxapine—Hypotension—Fluorouracil—pancreatic cancer	0.000672	0.00205	CcSEcCtD
Loxapine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000672	0.00205	CcSEcCtD
Loxapine—Rash—Tamoxifen—pancreatic cancer	0.000671	0.00205	CcSEcCtD
Loxapine—Dermatitis—Tamoxifen—pancreatic cancer	0.000671	0.00204	CcSEcCtD
Loxapine—Vomiting—Erlotinib—pancreatic cancer	0.00067	0.00204	CcSEcCtD
Loxapine—Dyspnoea—Irinotecan—pancreatic cancer	0.00067	0.00204	CcSEcCtD
Loxapine—Somnolence—Irinotecan—pancreatic cancer	0.000668	0.00203	CcSEcCtD
Loxapine—Headache—Tamoxifen—pancreatic cancer	0.000667	0.00203	CcSEcCtD
Loxapine—Rash—Erlotinib—pancreatic cancer	0.000664	0.00202	CcSEcCtD
Loxapine—Dermatitis—Erlotinib—pancreatic cancer	0.000663	0.00202	CcSEcCtD
Loxapine—Angiopathy—Docetaxel—pancreatic cancer	0.000663	0.00202	CcSEcCtD
Loxapine—Insomnia—Gemcitabine—pancreatic cancer	0.000662	0.00202	CcSEcCtD
Loxapine—Headache—Erlotinib—pancreatic cancer	0.00066	0.00201	CcSEcCtD
Loxapine—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000659	0.00201	CcSEcCtD
Loxapine—Paraesthesia—Gemcitabine—pancreatic cancer	0.000657	0.002	CcSEcCtD
Loxapine—Asthenia—Sunitinib—pancreatic cancer	0.000654	0.00199	CcSEcCtD
Loxapine—Dyspnoea—Gemcitabine—pancreatic cancer	0.000652	0.00199	CcSEcCtD
Loxapine—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000651	0.00198	CcSEcCtD
Loxapine—Insomnia—Fluorouracil—pancreatic cancer	0.000651	0.00198	CcSEcCtD
Loxapine—Somnolence—Gemcitabine—pancreatic cancer	0.00065	0.00198	CcSEcCtD
Loxapine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000648	0.00198	CcSEcCtD
Loxapine—Fatigue—Irinotecan—pancreatic cancer	0.000648	0.00197	CcSEcCtD
Loxapine—Paraesthesia—Fluorouracil—pancreatic cancer	0.000646	0.00197	CcSEcCtD
Loxapine—Alopecia—Docetaxel—pancreatic cancer	0.000646	0.00197	CcSEcCtD
Loxapine—Pruritus—Sunitinib—pancreatic cancer	0.000645	0.00197	CcSEcCtD
Loxapine—Constipation—Irinotecan—pancreatic cancer	0.000642	0.00196	CcSEcCtD
Loxapine—Dyspnoea—Fluorouracil—pancreatic cancer	0.000641	0.00195	CcSEcCtD
Loxapine—Somnolence—Fluorouracil—pancreatic cancer	0.000639	0.00195	CcSEcCtD
Loxapine—Nausea—Tamoxifen—pancreatic cancer	0.000632	0.00193	CcSEcCtD
Loxapine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000632	0.00192	CcSEcCtD
Loxapine—Fatigue—Gemcitabine—pancreatic cancer	0.000631	0.00192	CcSEcCtD
Loxapine—Constipation—Gemcitabine—pancreatic cancer	0.000626	0.00191	CcSEcCtD
Loxapine—Nausea—Erlotinib—pancreatic cancer	0.000626	0.00191	CcSEcCtD
Loxapine—Dysgeusia—Docetaxel—pancreatic cancer	0.000623	0.0019	CcSEcCtD
Loxapine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000621	0.00189	CcSEcCtD
Loxapine—Feeling abnormal—Irinotecan—pancreatic cancer	0.000619	0.00189	CcSEcCtD
Loxapine—Dysphagia—Epirubicin—pancreatic cancer	0.000616	0.00188	CcSEcCtD
Loxapine—Muscle spasms—Docetaxel—pancreatic cancer	0.000612	0.00186	CcSEcCtD
Loxapine—Dizziness—Sunitinib—pancreatic cancer	0.000603	0.00184	CcSEcCtD
Loxapine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000603	0.00184	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000602	0.00183	CcSEcCtD
Loxapine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000593	0.00181	CcSEcCtD
Loxapine—Vomiting—Sunitinib—pancreatic cancer	0.00058	0.00177	CcSEcCtD
Loxapine—Rash—Sunitinib—pancreatic cancer	0.000575	0.00175	CcSEcCtD
Loxapine—Dermatitis—Sunitinib—pancreatic cancer	0.000574	0.00175	CcSEcCtD
Loxapine—Headache—Sunitinib—pancreatic cancer	0.000571	0.00174	CcSEcCtD
Loxapine—Syncope—Docetaxel—pancreatic cancer	0.00057	0.00174	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—pancreatic cancer	0.00057	0.00174	CcSEcCtD
Loxapine—Leukopenia—Docetaxel—pancreatic cancer	0.000569	0.00174	CcSEcCtD
Loxapine—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000562	0.00171	CcSEcCtD
Loxapine—Weight increased—Epirubicin—pancreatic cancer	0.00056	0.00171	CcSEcCtD
Loxapine—Loss of consciousness—Docetaxel—pancreatic cancer	0.000559	0.0017	CcSEcCtD
Loxapine—Weight decreased—Epirubicin—pancreatic cancer	0.000557	0.0017	CcSEcCtD
Loxapine—Cough—Docetaxel—pancreatic cancer	0.000555	0.00169	CcSEcCtD
Loxapine—Hypersensitivity—Irinotecan—pancreatic cancer	0.000553	0.00169	CcSEcCtD
Loxapine—Convulsion—Docetaxel—pancreatic cancer	0.000551	0.00168	CcSEcCtD
Loxapine—Hypertension—Docetaxel—pancreatic cancer	0.000549	0.00167	CcSEcCtD
Loxapine—Drowsiness—Epirubicin—pancreatic cancer	0.000549	0.00167	CcSEcCtD
Loxapine—Chest pain—Docetaxel—pancreatic cancer	0.000542	0.00165	CcSEcCtD
Loxapine—Nausea—Sunitinib—pancreatic cancer	0.000542	0.00165	CcSEcCtD
Loxapine—Renal failure—Epirubicin—pancreatic cancer	0.00054	0.00164	CcSEcCtD
Loxapine—Asthenia—Irinotecan—pancreatic cancer	0.000539	0.00164	CcSEcCtD
Loxapine—Jaundice—Epirubicin—pancreatic cancer	0.000535	0.00163	CcSEcCtD
Loxapine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00053	0.00161	CcSEcCtD
Loxapine—Dry mouth—Docetaxel—pancreatic cancer	0.00053	0.00161	CcSEcCtD
Loxapine—Asthenia—Gemcitabine—pancreatic cancer	0.000525	0.0016	CcSEcCtD
Loxapine—Confusional state—Docetaxel—pancreatic cancer	0.000523	0.0016	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.00052	0.00158	CcSEcCtD
Loxapine—Oedema—Docetaxel—pancreatic cancer	0.000519	0.00158	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—pancreatic cancer	0.000519	0.00158	CcSEcCtD
Loxapine—Pruritus—Gemcitabine—pancreatic cancer	0.000518	0.00158	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—pancreatic cancer	0.000515	0.00157	CcSEcCtD
Loxapine—Agranulocytosis—Epirubicin—pancreatic cancer	0.000512	0.00156	CcSEcCtD
Loxapine—Shock—Docetaxel—pancreatic cancer	0.000511	0.00156	CcSEcCtD
Loxapine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000509	0.00155	CcSEcCtD
Loxapine—Pruritus—Fluorouracil—pancreatic cancer	0.000509	0.00155	CcSEcCtD
Loxapine—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000508	0.00155	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—pancreatic cancer	0.000508	0.00155	CcSEcCtD
Loxapine—Tachycardia—Docetaxel—pancreatic cancer	0.000507	0.00154	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—pancreatic cancer	0.000499	0.00152	CcSEcCtD
Loxapine—Dizziness—Irinotecan—pancreatic cancer	0.000497	0.00151	CcSEcCtD
Loxapine—Jaundice—Doxorubicin—pancreatic cancer	0.000495	0.00151	CcSEcCtD
Loxapine—Hepatitis—Epirubicin—pancreatic cancer	0.000493	0.0015	CcSEcCtD
Loxapine—Hypoaesthesia—Epirubicin—pancreatic cancer	0.00049	0.00149	CcSEcCtD
Loxapine—Hypotension—Docetaxel—pancreatic cancer	0.000485	0.00148	CcSEcCtD
Loxapine—Vomiting—Irinotecan—pancreatic cancer	0.000478	0.00146	CcSEcCtD
Loxapine—Dizziness—Fluorouracil—pancreatic cancer	0.000476	0.00145	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000474	0.00144	CcSEcCtD
Loxapine—Rash—Irinotecan—pancreatic cancer	0.000474	0.00144	CcSEcCtD
Loxapine—Dermatitis—Irinotecan—pancreatic cancer	0.000473	0.00144	CcSEcCtD
Loxapine—Headache—Irinotecan—pancreatic cancer	0.00047	0.00143	CcSEcCtD
Loxapine—Insomnia—Docetaxel—pancreatic cancer	0.00047	0.00143	CcSEcCtD
Loxapine—Paraesthesia—Docetaxel—pancreatic cancer	0.000466	0.00142	CcSEcCtD
Loxapine—Vomiting—Gemcitabine—pancreatic cancer	0.000465	0.00142	CcSEcCtD
Loxapine—Dyspnoea—Docetaxel—pancreatic cancer	0.000463	0.00141	CcSEcCtD
Loxapine—Somnolence—Docetaxel—pancreatic cancer	0.000462	0.00141	CcSEcCtD
Loxapine—Rash—Gemcitabine—pancreatic cancer	0.000461	0.00141	CcSEcCtD
Loxapine—Dermatitis—Gemcitabine—pancreatic cancer	0.000461	0.0014	CcSEcCtD
Loxapine—Headache—Gemcitabine—pancreatic cancer	0.000458	0.0014	CcSEcCtD
Loxapine—Vomiting—Fluorouracil—pancreatic cancer	0.000457	0.00139	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—pancreatic cancer	0.000456	0.00139	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000454	0.00138	CcSEcCtD
Loxapine—Rash—Fluorouracil—pancreatic cancer	0.000454	0.00138	CcSEcCtD
Loxapine—Dermatitis—Fluorouracil—pancreatic cancer	0.000453	0.00138	CcSEcCtD
Loxapine—Headache—Fluorouracil—pancreatic cancer	0.000451	0.00137	CcSEcCtD
Loxapine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000448	0.00137	CcSEcCtD
Loxapine—Fatigue—Docetaxel—pancreatic cancer	0.000448	0.00136	CcSEcCtD
Loxapine—Angiopathy—Epirubicin—pancreatic cancer	0.000447	0.00136	CcSEcCtD
Loxapine—Nausea—Irinotecan—pancreatic cancer	0.000446	0.00136	CcSEcCtD
Loxapine—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000444	0.00135	CcSEcCtD
Loxapine—Constipation—Docetaxel—pancreatic cancer	0.000444	0.00135	CcSEcCtD
Loxapine—Alopecia—Epirubicin—pancreatic cancer	0.000436	0.00133	CcSEcCtD
Loxapine—Nausea—Gemcitabine—pancreatic cancer	0.000435	0.00132	CcSEcCtD
Loxapine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000428	0.0013	CcSEcCtD
Loxapine—Nausea—Fluorouracil—pancreatic cancer	0.000427	0.0013	CcSEcCtD
Loxapine—Tension—Epirubicin—pancreatic cancer	0.000421	0.00128	CcSEcCtD
Loxapine—Dysgeusia—Epirubicin—pancreatic cancer	0.00042	0.00128	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—pancreatic cancer	0.000414	0.00126	CcSEcCtD
Loxapine—Muscle spasms—Epirubicin—pancreatic cancer	0.000413	0.00126	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000411	0.00125	CcSEcCtD
Loxapine—Vision blurred—Epirubicin—pancreatic cancer	0.000404	0.00123	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—pancreatic cancer	0.000403	0.00123	CcSEcCtD
Loxapine—Agitation—Epirubicin—pancreatic cancer	0.000394	0.0012	CcSEcCtD
Loxapine—Tension—Doxorubicin—pancreatic cancer	0.00039	0.00119	CcSEcCtD
Loxapine—Dysgeusia—Doxorubicin—pancreatic cancer	0.000389	0.00118	CcSEcCtD
Loxapine—Syncope—Epirubicin—pancreatic cancer	0.000385	0.00117	CcSEcCtD
Loxapine—Leukopenia—Epirubicin—pancreatic cancer	0.000384	0.00117	CcSEcCtD
Loxapine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000382	0.00117	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—pancreatic cancer	0.000382	0.00116	CcSEcCtD
Loxapine—Loss of consciousness—Epirubicin—pancreatic cancer	0.000377	0.00115	CcSEcCtD
Loxapine—Cough—Epirubicin—pancreatic cancer	0.000374	0.00114	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—pancreatic cancer	0.000374	0.00114	CcSEcCtD
Loxapine—Asthenia—Docetaxel—pancreatic cancer	0.000372	0.00114	CcSEcCtD
Loxapine—Convulsion—Epirubicin—pancreatic cancer	0.000372	0.00113	CcSEcCtD
Loxapine—Hypertension—Epirubicin—pancreatic cancer	0.00037	0.00113	CcSEcCtD
Loxapine—Pruritus—Docetaxel—pancreatic cancer	0.000367	0.00112	CcSEcCtD
Loxapine—Chest pain—Epirubicin—pancreatic cancer	0.000365	0.00111	CcSEcCtD
Loxapine—Agitation—Doxorubicin—pancreatic cancer	0.000365	0.00111	CcSEcCtD
Loxapine—Dry mouth—Epirubicin—pancreatic cancer	0.000357	0.00109	CcSEcCtD
Loxapine—Syncope—Doxorubicin—pancreatic cancer	0.000356	0.00108	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—pancreatic cancer	0.000355	0.00108	CcSEcCtD
Loxapine—Confusional state—Epirubicin—pancreatic cancer	0.000353	0.00108	CcSEcCtD
Loxapine—Oedema—Epirubicin—pancreatic cancer	0.00035	0.00107	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000349	0.00106	CcSEcCtD
Loxapine—Cough—Doxorubicin—pancreatic cancer	0.000346	0.00106	CcSEcCtD
Loxapine—Shock—Epirubicin—pancreatic cancer	0.000345	0.00105	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—pancreatic cancer	0.000344	0.00105	CcSEcCtD
Loxapine—Nervous system disorder—Epirubicin—pancreatic cancer	0.000343	0.00105	CcSEcCtD
Loxapine—Dizziness—Docetaxel—pancreatic cancer	0.000343	0.00105	CcSEcCtD
Loxapine—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000343	0.00104	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—pancreatic cancer	0.000343	0.00104	CcSEcCtD
Loxapine—Tachycardia—Epirubicin—pancreatic cancer	0.000342	0.00104	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—pancreatic cancer	0.000338	0.00103	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—pancreatic cancer	0.000331	0.00101	CcSEcCtD
Loxapine—Vomiting—Docetaxel—pancreatic cancer	0.00033	0.00101	CcSEcCtD
Loxapine—Rash—Docetaxel—pancreatic cancer	0.000327	0.000997	CcSEcCtD
Loxapine—Hypotension—Epirubicin—pancreatic cancer	0.000327	0.000997	CcSEcCtD
Loxapine—Dermatitis—Docetaxel—pancreatic cancer	0.000327	0.000997	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—pancreatic cancer	0.000327	0.000996	CcSEcCtD
Loxapine—Headache—Docetaxel—pancreatic cancer	0.000325	0.000991	CcSEcCtD
Loxapine—Oedema—Doxorubicin—pancreatic cancer	0.000324	0.000987	CcSEcCtD
Loxapine—Shock—Doxorubicin—pancreatic cancer	0.000319	0.000971	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000318	0.000968	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000317	0.000967	CcSEcCtD
Loxapine—Insomnia—Epirubicin—pancreatic cancer	0.000317	0.000965	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—pancreatic cancer	0.000316	0.000964	CcSEcCtD
Loxapine—Paraesthesia—Epirubicin—pancreatic cancer	0.000314	0.000958	CcSEcCtD
Loxapine—Dyspnoea—Epirubicin—pancreatic cancer	0.000312	0.000951	CcSEcCtD
Loxapine—Somnolence—Epirubicin—pancreatic cancer	0.000311	0.000949	CcSEcCtD
Loxapine—Nausea—Docetaxel—pancreatic cancer	0.000308	0.00094	CcSEcCtD
Loxapine—Hypotension—Doxorubicin—pancreatic cancer	0.000303	0.000923	CcSEcCtD
Loxapine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000302	0.000921	CcSEcCtD
Loxapine—Fatigue—Epirubicin—pancreatic cancer	0.000302	0.00092	CcSEcCtD
Loxapine—Constipation—Epirubicin—pancreatic cancer	0.000299	0.000912	CcSEcCtD
Loxapine—Insomnia—Doxorubicin—pancreatic cancer	0.000293	0.000893	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000291	0.000887	CcSEcCtD
Loxapine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000289	0.00088	CcSEcCtD
Loxapine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000289	0.000879	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—pancreatic cancer	0.000288	0.000878	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.00028	0.000852	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—pancreatic cancer	0.000279	0.000851	CcSEcCtD
Loxapine—Constipation—Doxorubicin—pancreatic cancer	0.000277	0.000844	CcSEcCtD
Loxapine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000267	0.000814	CcSEcCtD
Loxapine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000258	0.000786	CcSEcCtD
Loxapine—Asthenia—Epirubicin—pancreatic cancer	0.000251	0.000766	CcSEcCtD
Loxapine—Pruritus—Epirubicin—pancreatic cancer	0.000248	0.000755	CcSEcCtD
Loxapine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000239	0.000727	CcSEcCtD
Loxapine—Asthenia—Doxorubicin—pancreatic cancer	0.000232	0.000708	CcSEcCtD
Loxapine—Dizziness—Epirubicin—pancreatic cancer	0.000232	0.000706	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—pancreatic cancer	0.000229	0.000699	CcSEcCtD
Loxapine—Vomiting—Epirubicin—pancreatic cancer	0.000223	0.000678	CcSEcCtD
Loxapine—Rash—Epirubicin—pancreatic cancer	0.000221	0.000673	CcSEcCtD
Loxapine—Dermatitis—Epirubicin—pancreatic cancer	0.000221	0.000672	CcSEcCtD
Loxapine—Headache—Epirubicin—pancreatic cancer	0.000219	0.000668	CcSEcCtD
Loxapine—Dizziness—Doxorubicin—pancreatic cancer	0.000214	0.000653	CcSEcCtD
Loxapine—Nausea—Epirubicin—pancreatic cancer	0.000208	0.000634	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—pancreatic cancer	0.000206	0.000628	CcSEcCtD
Loxapine—Rash—Doxorubicin—pancreatic cancer	0.000204	0.000623	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—pancreatic cancer	0.000204	0.000622	CcSEcCtD
Loxapine—Headache—Doxorubicin—pancreatic cancer	0.000203	0.000619	CcSEcCtD
Loxapine—Nausea—Doxorubicin—pancreatic cancer	0.000192	0.000586	CcSEcCtD
Loxapine—CHRM3—GPCR downstream signaling—AKT1—pancreatic cancer	8.29e-06	1.58e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	8.29e-06	1.57e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CASP3—pancreatic cancer	8.27e-06	1.57e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TP53—pancreatic cancer	8.25e-06	1.57e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	8.24e-06	1.57e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CASP3—pancreatic cancer	8.22e-06	1.56e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	8.21e-06	1.56e-05	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—AKT1—pancreatic cancer	8.21e-06	1.56e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCND1—pancreatic cancer	8.2e-06	1.56e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	8.2e-06	1.56e-05	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	8.19e-06	1.56e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	8.14e-06	1.55e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CASP3—pancreatic cancer	8.14e-06	1.55e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	8.12e-06	1.54e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	8.11e-06	1.54e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—PIK3CA—pancreatic cancer	8.1e-06	1.54e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	8.1e-06	1.54e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	8.09e-06	1.54e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—pancreatic cancer	8.07e-06	1.53e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	8.07e-06	1.53e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	8.06e-06	1.53e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCND1—pancreatic cancer	8.05e-06	1.53e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—KRAS—pancreatic cancer	8.05e-06	1.53e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	8.04e-06	1.53e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	8.02e-06	1.52e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	8.02e-06	1.52e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	8e-06	1.52e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCND1—pancreatic cancer	8e-06	1.52e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	7.99e-06	1.52e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	7.97e-06	1.51e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	7.96e-06	1.51e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MMP9—pancreatic cancer	7.96e-06	1.51e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—HRAS—pancreatic cancer	7.95e-06	1.51e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	7.95e-06	1.51e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—pancreatic cancer	7.95e-06	1.51e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KRAS—pancreatic cancer	7.94e-06	1.51e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—HRAS—pancreatic cancer	7.94e-06	1.51e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	7.92e-06	1.5e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CTNNB1—pancreatic cancer	7.92e-06	1.5e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PTEN—pancreatic cancer	7.91e-06	1.5e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	7.9e-06	1.5e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	7.89e-06	1.5e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	7.88e-06	1.5e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	7.88e-06	1.5e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	7.84e-06	1.49e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—pancreatic cancer	7.84e-06	1.49e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	7.83e-06	1.49e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—pancreatic cancer	7.83e-06	1.49e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	7.83e-06	1.49e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	7.82e-06	1.49e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—pancreatic cancer	7.81e-06	1.48e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	7.81e-06	1.48e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	7.8e-06	1.48e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	7.79e-06	1.48e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	7.79e-06	1.48e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	7.78e-06	1.48e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—pancreatic cancer	7.77e-06	1.48e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—pancreatic cancer	7.76e-06	1.48e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—pancreatic cancer	7.76e-06	1.47e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	7.76e-06	1.47e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	7.75e-06	1.47e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	7.74e-06	1.47e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	7.74e-06	1.47e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	7.72e-06	1.47e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	7.72e-06	1.47e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—pancreatic cancer	7.72e-06	1.47e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	7.69e-06	1.46e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	7.68e-06	1.46e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	7.67e-06	1.46e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	7.66e-06	1.46e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	7.66e-06	1.45e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	7.64e-06	1.45e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	7.62e-06	1.45e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	7.61e-06	1.45e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—pancreatic cancer	7.6e-06	1.44e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	7.6e-06	1.44e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	7.59e-06	1.44e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	7.58e-06	1.44e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	7.56e-06	1.44e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	7.54e-06	1.43e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—pancreatic cancer	7.53e-06	1.43e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—pancreatic cancer	7.51e-06	1.43e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—pancreatic cancer	7.5e-06	1.42e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—pancreatic cancer	7.49e-06	1.42e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	7.47e-06	1.42e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	7.46e-06	1.42e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—pancreatic cancer	7.45e-06	1.42e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	7.44e-06	1.41e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	7.43e-06	1.41e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	7.39e-06	1.4e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	7.36e-06	1.4e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	7.34e-06	1.39e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—SRC—pancreatic cancer	7.34e-06	1.39e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	7.33e-06	1.39e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	7.3e-06	1.39e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	7.29e-06	1.38e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	7.27e-06	1.38e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	7.25e-06	1.38e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	7.23e-06	1.37e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	7.23e-06	1.37e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—SRC—pancreatic cancer	7.22e-06	1.37e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—SRC—pancreatic cancer	7.2e-06	1.37e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—SRC—pancreatic cancer	7.18e-06	1.36e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—pancreatic cancer	7.18e-06	1.36e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	7.17e-06	1.36e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—SRC—pancreatic cancer	7.16e-06	1.36e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—pancreatic cancer	7.15e-06	1.36e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	7.15e-06	1.36e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	7.13e-06	1.36e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	7.12e-06	1.35e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	7.12e-06	1.35e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SRC—pancreatic cancer	7.09e-06	1.35e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	7.09e-06	1.35e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	7.08e-06	1.35e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—pancreatic cancer	7.08e-06	1.34e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	7.07e-06	1.34e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NRAS—pancreatic cancer	7.06e-06	1.34e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—pancreatic cancer	7.06e-06	1.34e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	7.03e-06	1.34e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	7.02e-06	1.33e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—pancreatic cancer	7.02e-06	1.33e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—pancreatic cancer	7.01e-06	1.33e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	6.99e-06	1.33e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	6.98e-06	1.33e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—pancreatic cancer	6.97e-06	1.32e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	6.96e-06	1.32e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	6.96e-06	1.32e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—pancreatic cancer	6.95e-06	1.32e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	6.95e-06	1.32e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NRAS—pancreatic cancer	6.93e-06	1.32e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	6.93e-06	1.32e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	6.92e-06	1.31e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	6.91e-06	1.31e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	6.91e-06	1.31e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	6.9e-06	1.31e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—pancreatic cancer	6.9e-06	1.31e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NRAS—pancreatic cancer	6.89e-06	1.31e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	6.89e-06	1.31e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	6.88e-06	1.31e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—pancreatic cancer	6.84e-06	1.3e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	6.84e-06	1.3e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	6.82e-06	1.3e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	6.82e-06	1.3e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	6.82e-06	1.3e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	6.8e-06	1.29e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—pancreatic cancer	6.75e-06	1.28e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—pancreatic cancer	6.71e-06	1.27e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	6.7e-06	1.27e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	6.65e-06	1.26e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—pancreatic cancer	6.62e-06	1.26e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	6.59e-06	1.25e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	6.59e-06	1.25e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—pancreatic cancer	6.58e-06	1.25e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	6.57e-06	1.25e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	6.56e-06	1.25e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—pancreatic cancer	6.51e-06	1.24e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—pancreatic cancer	6.47e-06	1.23e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—pancreatic cancer	6.46e-06	1.23e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	6.45e-06	1.23e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	6.44e-06	1.22e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—pancreatic cancer	6.44e-06	1.22e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—pancreatic cancer	6.43e-06	1.22e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—pancreatic cancer	6.43e-06	1.22e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	6.42e-06	1.22e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—pancreatic cancer	6.42e-06	1.22e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TGFB1—pancreatic cancer	6.4e-06	1.22e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	6.4e-06	1.22e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	6.37e-06	1.21e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	6.36e-06	1.21e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—pancreatic cancer	6.35e-06	1.21e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—pancreatic cancer	6.34e-06	1.2e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	6.34e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	6.34e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	6.33e-06	1.2e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	6.33e-06	1.2e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	6.33e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	6.32e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	6.32e-06	1.2e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—pancreatic cancer	6.31e-06	1.2e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	6.29e-06	1.2e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—pancreatic cancer	6.27e-06	1.19e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	6.21e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	6.2e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	6.15e-06	1.17e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—pancreatic cancer	6.15e-06	1.17e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	6.15e-06	1.17e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—pancreatic cancer	6.12e-06	1.16e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	6.09e-06	1.16e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—pancreatic cancer	6.08e-06	1.15e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	6.05e-06	1.15e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—pancreatic cancer	6.04e-06	1.15e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—pancreatic cancer	6.01e-06	1.14e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	5.98e-06	1.14e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	5.98e-06	1.14e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—pancreatic cancer	5.97e-06	1.13e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—pancreatic cancer	5.96e-06	1.13e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	5.95e-06	1.13e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	5.95e-06	1.13e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—pancreatic cancer	5.93e-06	1.13e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	5.89e-06	1.12e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	5.88e-06	1.12e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	5.87e-06	1.12e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	5.87e-06	1.12e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	5.86e-06	1.11e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	5.85e-06	1.11e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	5.85e-06	1.11e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	5.76e-06	1.09e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	5.69e-06	1.08e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	5.6e-06	1.06e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	5.58e-06	1.06e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	5.49e-06	1.04e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	5.48e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	5.46e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—pancreatic cancer	5.45e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	5.44e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	5.43e-06	1.03e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—pancreatic cancer	5.4e-06	1.03e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	5.39e-06	1.02e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	5.38e-06	1.02e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	5.38e-06	1.02e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—pancreatic cancer	5.32e-06	1.01e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—pancreatic cancer	5.31e-06	1.01e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—pancreatic cancer	5.3e-06	1.01e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—pancreatic cancer	5.29e-06	1e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—pancreatic cancer	5.27e-06	1e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—pancreatic cancer	5.22e-06	9.91e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	5.2e-06	9.89e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	5.19e-06	9.87e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	5.17e-06	9.82e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—pancreatic cancer	5.16e-06	9.81e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	5.08e-06	9.66e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—pancreatic cancer	5.07e-06	9.63e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	5.05e-06	9.6e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—pancreatic cancer	5.04e-06	9.57e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	5.03e-06	9.55e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	5e-06	9.49e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	4.99e-06	9.48e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	4.98e-06	9.45e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	4.95e-06	9.4e-06	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—pancreatic cancer	4.88e-06	9.28e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	4.83e-06	9.18e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	4.62e-06	8.78e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—pancreatic cancer	4.56e-06	8.66e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	4.49e-06	8.53e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—pancreatic cancer	4.48e-06	8.51e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	4.46e-06	8.48e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—pancreatic cancer	4.45e-06	8.45e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	4.41e-06	8.37e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	4.39e-06	8.35e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	4.08e-06	7.76e-06	CbGpPWpGaD
